AnaptysBio, Inc. (ANAB) has a consensus analyst rating of Buy, based on 21 analysts covering the stock. Of those, 15 recommend buying, 6 recommend holding, and 0 recommend selling.
The analyst consensus price target for ANAB is $73.71, representing a +5.0% upside from the current price of $70.22. Price targets range from a low of $50.00 to a high of $140.00.
